Active Ingredient History

  • Now
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. Development of galunisertib by Eli Lilly was discontinued in January 2020.   Wikipedia

  • SMILES: Cc1cccc(n1)c2nn3CCCc3c2c4ccnc5ccc(cc45)C(=O)N
  • Mol. Mass: 369.43
  • ALogP: 3.51
  • ChEMBL Molecule:
More Chemistry
4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo(1,2-b)pyrazol-3-yl)quinoline-6-carboxylic acid amide | galunisertib | ly2157299 | ly 2157299 | ly-2157299


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue